17 Oct 2022 07:00
RNS Number : 9972C OptiBiotix Health PLC 17 October 2022 160OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
160
New health claims for SlimBiome174 in Australia
160
OptiBiotix Health plc (AIM: OPTI), a life sciences business eveloping compouns to tackle obesity, cariovascular isease an iabetes, announces aitional new health claims for SlimBiome174 containing proucts in Australia.160 This will help to further ifferentiate an avance their market share in health wellness, sports nutrition an weight management markets.
160
In accorance with the Australia New Zealan Foo Stanars Coe ("FSANZ"), OptiBiotix has complete a systematic review of the scientific literature for its prebiotic weight management ai SlimBiome174 which allows it to make four new general level health claims on their prouct packaging an general avertising. These claims are:
160
-160160160160 SlimBiome174 contributes to the enhancement of the feelings of fullness an helps you stay fuller for longer
-160160160160 SlimBiome174 contributes to the enhancement of satiety, feelings of fullness, reuce feelings of hunger, foo cravings an the esire to eat
- 160 SlimBiome174 supports igestive health by maintaining an/or improving the gut microbiome, by promoting gut microbiome iversity an a healthy intestinal bacterial balance
-160160160160 SlimBiome174 supports an improves igestive health by promoting the growth an iversity of beneficial bacteria in the gut
160
The systematic review evaluates whether there is sufficient evience to establish a relationship between a foo or property of foo an a health effect (foo-health relationship) an inclues an extensive review an ranking of ata, assessment of quality of the stuies an preparation of a ossier to meet requirements of Scheule Six of the FSANZ.
160
The extensive ossier built by OptiBiotix enables OptiBiotix partners in Australia to notify FSANZ an apply these claims to communicate the key Unique Selling Points (USPs) of their proucts containing SlimBiome174 which will help ifferentiate their proucts from, an gain market share against, mainstream competitors an stan out in the health wellness, weight management an sports nutrition categories.
160
SlimBiome174 is a patente prebiotic weight management ai use as such or in formulate proucts in the health wellness, sports nutrition an weight management categories. SlimBiome174 is supporte by inepenent human clinical stuies which show it reuces hunger, cravings for sweet an savoury foos, an fat intake.160It helps people stick to the iet plan they have unertaken. Consumers who use SlimBiome174 in combination with a calorie restricte iet experience a relief from feeling hungry an have fewer cravings for foo, leaing to easier an more sustainable ieting an lose on average an aitional 2kg of fat per month, improving boy composition.
160
SlimBiome174 has achieve multiple inustry awars. The three major awars are: European Weight Management Ingreient of the Year (NutraIngreients 2018), Asia Weight Management Ingreient of the Year (NutraIngreients 2019), an most recently, best weight management prouct in the USA (Nutrition Inustry Executive Awar 2021). Depening on the market, SlimBiome174 is also markete uner traenames OptiBiome174 an LeanBiome174.
160
Ren233 Kamminga, CEO of OptiBiotix Limite, a wholly owne subsiiary of OptiBiotix Health plc, commente: "This important step forwar enables our customers in Australia to notify FSANZ through a simple process an make health claims that are meaningful to their consumers that clearly ifferentiate their proucts from mainstream competition. It emonstrates our commitment to grow with our chosen customers an this will further accelerate the growth in our market position in Australia both online an offline in pharmacy an retail channels. SlimBiome174 now carries health claims with the European Foo Safety Authority (EFSA), with Health Canaa an FSANZ, some of the most challenging regulatory environments worlwie. It truly gives brans in health wellness, sports nutrition an weight management the science to stan out in their category. I want to specifically thank our scientific an regulatory team who put a great effort in to make this possible."
160
For further information, please contact:
160
160
This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information containe in this announcement is of a non-regulatory nature. Information require to be notifie uner the AIM Rules for Companies, Market Abuse Regulation or other regulation woul be isseminate as an RNS regulatory announcement an not on RNS Reach.
This information is provie by Reach, the non-regulatory press release istribution service of RNS, part of the Lonon Stock Exchange. Terms an conitions relating to the use an istribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information containe within this announcement is of a non-regulatory nature. Reach announcements are ientifie with an orange label an the wor 8220Reach8221 in the source column of the News Explorer pages of Lonon Stock Exchange8217s website so that they are istinguishe from the RNS UK regulatory service. Other venors subscribing for Reach press releases may use a ifferent metho to istinguish Reach announcements from UK regulatory news.RNS may use your IP aress to confirm compliance with the terms an conitions, to analyse how you engage with the information containe in this communication, an to share such analysis on an anonymise basis with others as part of our commercial services. For further information about how RNS an the Lonon Stock Exchange use the personal ata you provie us, please see our Privacy Policy.160 END160160NRAUSAVRUBURAAA
OptiBiotix Health (OPTI)